Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Science & Technology (10)
- Gastroenterology & Hepatology (9)
- Life Sciences & Biomedicine (9)
- COMBINATION (3)
- RIBAVIRIN (3)
-
- ABT-450/R-OMBITASVIR (2)
- COVID-19 (2)
- DASABUVIR (2)
- ELBASVIR (2)
- INFECTION (2)
- MORTALITY (2)
- NS5A (2)
- PEGYLATED INTERFERON (2)
- REGIMENS (2)
- ACUTE KIDNEY INJURY (1)
- AKI (1)
- ANEMIA (1)
- ASSOCIATION (1)
- Anaemia (1)
- Antiviral activity;; hcv infection;; ns5a;; inhibitors;; ribavirin;; risk;; Gastroenterology & Hepatology (1)
- C3A CELLS (1)
- CHINA (1)
- CHRONIC HCV (1)
- CHRONIC HEPATITIS (1)
- CHRONIC HEPATITIS-C (1)
- CIRRHOSIS (1)
- CLINICAL-TRIALS (1)
- COMPENSATED CIRRHOSIS (1)
- CONFERS SUSCEPTIBILITY (1)
- CORONAVIRUS DISEASE (1)
Articles 1 - 25 of 25
Full-Text Articles in Hepatology
Covid-19 Presenting As Acute Hepatitis, P. Wander, M. Epstein, D. Bernstein
Covid-19 Presenting As Acute Hepatitis, P. Wander, M. Epstein, D. Bernstein
Journal Articles
No abstract provided.
Peri-Transplant Management Of Nonalcoholic Fatty Liver Disease In Liver Transplant Candidates, N. S. Samji, R. Heda, S. K. Satapathy
Peri-Transplant Management Of Nonalcoholic Fatty Liver Disease In Liver Transplant Candidates, N. S. Samji, R. Heda, S. K. Satapathy
Journal Articles
© Translational Gastroenterology and Hepatology. All rights reserved. The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly growing, affecting 25% of the world population. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD and affects 1.5% to 6.5% of the world population. Its rising incidence will make end-stage liver disease (ESLD) due to NASH the number one indication for liver transplantation (LT) in the next 10 to 20 years, overtaking Hepatitis C. Patients with NASH also have a high prevalence of associated comorbidities such as type 2 diabetes, obesity, metabolic syndrome, cardiovascular disease, and chronic kidney disease (CKD), …
Acute Liver Failure In A Covid-19 Patient Without Any Preexisting Liver Disease., D. Gurala, H. Al Moussawi, J. Philipose, J. R. Abergel
Acute Liver Failure In A Covid-19 Patient Without Any Preexisting Liver Disease., D. Gurala, H. Al Moussawi, J. Philipose, J. R. Abergel
Journal Articles
In December 2019, an outbreak of novel coronavirus started in Wuhan, China, which gradually spread to the entire world. The World Health Organization (WHO) on February 11, 2020, officially announced the name for the disease as coronavirus disease 2019, abbreviated as COVID-19. It is caused by severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2). The WHO declared SARS-CoV-2 as a pandemic on March 11, 2020. SARS-CoV-2 mainly causes fever as well as respiratory symptoms such as cough and shortness of breath. Gastrointestinal/hepatic sequelae such as diarrhea, nausea, vomiting, and elevated liver enzymes have been reported as well. Studies and data so …
Elevated Liver Biochemistries In Hospitalized Chinese Patients With Severe Covid-19: Systematic Review And Meta-Analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, S. K. Satapathy
Elevated Liver Biochemistries In Hospitalized Chinese Patients With Severe Covid-19: Systematic Review And Meta-Analysis., A. J. Kovalic, G. Huang, P. J. Thuluvath, S. K. Satapathy
Journal Articles
BACKGROUND & AIMS:Several recent studies have reported an abnormal liver chemistry profile among patients with coronavirus disease 2019 (COVID-19), although its clinical significance remains unknown. APPROACH & RESULTS:This novel systematic review and meta-analysis identified six studies of 586 patients delineating liver chemistries among patients with severe/critical illness versus mild cases of COVID-19 infection. Patients with severe/critical illness with COVID-19 infection have increased prevalence of coronary artery disease (CAD), cerebrovascular disease, and chronic obstructive pulmonary disease (COPD) as compared to mild cases. A significant association between severe/critical COVID-19 infections with elevations in aspartate aminotransferase (AST) (pooled mean difference [MD], 11.70 U/L; …
Prevalence Of Chronic Liver Disease In Patients With Covid-19 And Their Clinical Outcomes: A Systematic Review And Meta-Analysis, A. J. Kovalic, S. K. Satapathy, P. J. Thuluvath
Prevalence Of Chronic Liver Disease In Patients With Covid-19 And Their Clinical Outcomes: A Systematic Review And Meta-Analysis, A. J. Kovalic, S. K. Satapathy, P. J. Thuluvath
Journal Articles
No abstract provided.
What Gi Physicians Need To Know During Covid-19 Pandemic, P. J. Thuluvath, J. J. Alukal, N. Ravindran, S. K. Satapathy
What Gi Physicians Need To Know During Covid-19 Pandemic, P. J. Thuluvath, J. J. Alukal, N. Ravindran, S. K. Satapathy
Journal Articles
No abstract provided.
Role Of Nutraceuticals In Covid-19 Mediated Liver Dysfunction., M. Sikander, S. Malik, A. Rodriguez, M. M. Yallapu, A. S. Narula, S. K. Satapathy, V. Dhevan, S. C. Chauhan, M. Jaggi
Role Of Nutraceuticals In Covid-19 Mediated Liver Dysfunction., M. Sikander, S. Malik, A. Rodriguez, M. M. Yallapu, A. S. Narula, S. K. Satapathy, V. Dhevan, S. C. Chauhan, M. Jaggi
Journal Articles
COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread of this deadly virus at incredible speed has stunned the planet and poses a challenge to global scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy is gaining importance and is an area of great concern. Currently, alternatives therapies are being sought to mitigate hepatic damage, and there has been growing interest in the research on bioactive phytochemical agents (nutraceuticals) due to their versatility in health benefits reported …
Association Between Longer Hospitalization And Development Of De Novo Donor Specific Antibodies In Simultaneous Liver–Kidney Transplant Recipients, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, S. Fossey, S. K. Satapathy, J. D. Eason, M. Z. Molnar
Association Between Longer Hospitalization And Development Of De Novo Donor Specific Antibodies In Simultaneous Liver–Kidney Transplant Recipients, M. Yazawa, O. Cseprekal, R. A. Helmick, M. Talwar, V. Balaraman, P. S. Podila, S. Fossey, S. K. Satapathy, J. D. Eason, M. Z. Molnar
Journal Articles
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. Background:De novo Donor Specific Antibodies (DSA) are considered as a risk factor for the kidney allograft outcomes in recipients after simultaneous liver–kidney transplantation (SLKT). We hypothesized that length of hospital stay (LOS) might be associated with de novo DSA development of due to the increased likelihood of receiving blood transfusions with reduced immunosuppressive regimens. Methods: This study is a single-center, retrospective cohort study consisting of 85 recipients who underwent SLKT from 2009 to 2018 in our hospital. We divided the patients into two …
Accuracy Of Noninvasive Fibrosis Scoring Systems In African American And White Patients With Nonalcoholic Fatty Liver Disease, H. K. Marella, Y. K. Reddy, Y. Jiang, S. Ganguli, P. S. Podila, P. D. Snell, A. J. Kovalic, G. Cholankeril, A. K. Singal, S. K. Satapathy, +2 Additional Authors
Accuracy Of Noninvasive Fibrosis Scoring Systems In African American And White Patients With Nonalcoholic Fatty Liver Disease, H. K. Marella, Y. K. Reddy, Y. Jiang, S. Ganguli, P. S. Podila, P. D. Snell, A. J. Kovalic, G. Cholankeril, A. K. Singal, S. K. Satapathy, +2 Additional Authors
Journal Articles
No abstract provided.
Prevalence And Profile Of Nonalcoholic Fatty Liver Disease In Lean Adults: Systematic Review And Meta-Analysis., S. Young, R. Tariq, J. Provenza, S. K. Satapathy, K. Faisal, A. Choudhry, S. L. Friedman, A. K. Singal
Prevalence And Profile Of Nonalcoholic Fatty Liver Disease In Lean Adults: Systematic Review And Meta-Analysis., S. Young, R. Tariq, J. Provenza, S. K. Satapathy, K. Faisal, A. Choudhry, S. L. Friedman, A. K. Singal
Journal Articles
Data on prevalence and profile of nonalcoholic fatty liver disease (NAFLD) among individuals who are lean (normal body mass index) is unclear. Published data from studies comparing lean with obese NAFLD or with healthy subjects on prevalence, comorbidities, liver chemistry and histology, and metabolic/inflammatory markers were analyzed. Data were reported as odds ratio and 95% confidence interval for categorical variables and difference of means for continuous variables. Analysis of 53 studies on 65,029 subjects with NAFLD (38,084 lean) and 249,544 healthy subjects showed a prevalence of lean NAFLD at 11.2% in the general population. Among individuals with NAFLD, the prevalence …
Outcomes Of Liver Transplant Recipients With Acute-On-Chronic Liver Failure Based On Easl-Clif Consortium Definition: A Single-Center Study, U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H. Gonzalez, S. K. Satapathy, +3 Additional Authors
Outcomes Of Liver Transplant Recipients With Acute-On-Chronic Liver Failure Based On Easl-Clif Consortium Definition: A Single-Center Study, U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H. Gonzalez, S. K. Satapathy, +3 Additional Authors
Journal Articles
© 2020 Cambridge University Press. All rights reserved. Background. The impact of acute-on-chronic liver failure (ACLF) defined by European Association for the Study of the Liver-Chronic Liver Failure in liver transplant (LT) recipients has not been well characterized. The aim of the study was to assess early posttransplant morbidity and survival of ACLF patients. Methods. Eight hundred twenty-five consecutive LT patients (04/2006-03/2013) were included in a retrospective analysis. Of the 690 evaluable patients, 589 had no ACLF, and the remaining 101 were grouped into ACLF Grades 1-3 (ACLF Grade 1: 50 [49.5%], ACLF Grade 2: 32 [31.7%], and ACLF Grade …
Nafld Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications And The Trends In The United States, C. Gadiparthi, M. Spatz, S. Greenberg, U. Iqbal, S. Kanna, S. K. Satapathy, A. Broder, A. Ahmed
Nafld Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications And The Trends In The United States, C. Gadiparthi, M. Spatz, S. Greenberg, U. Iqbal, S. Kanna, S. K. Satapathy, A. Broder, A. Ahmed
Journal Articles
© 2020 Authors. Nonalcoholic fatty liver disease (NAFLD) is a hepatic mani-festation of metabolic syndrome. The spread of obesity worldwide in pandemic proportions has led to a rapid rise of NAFLD in developed and developing countries alike. There are no approved pharmacological agents to treat steatohepatitis or advanced fibrosis but obeticholic acid recently has shown some promise in phase III trial. Currently, NAFLD is the number one etiology for simultaneous liver and kidney transplantation in the USA, second most common indication for liver transplantation (LT) and projected to become number one very soon. LT for NAFLD poses unique challenges, as …
Racial Disparities In Diagnosis And Prognosis Of Nonalcoholic Fatty Liver Disease, N. S. Samji, P. D. Snell, A. K. Singal, S. K. Satapathy
Racial Disparities In Diagnosis And Prognosis Of Nonalcoholic Fatty Liver Disease, N. S. Samji, P. D. Snell, A. K. Singal, S. K. Satapathy
Journal Articles
No abstract provided.
Longitudinal Renal Function In Liver Transplant Recipients With Acute-On-Chronic Liver Failure, M. Yazawa, B. Maliakkal, S. Nair, P. S. Podila, U. A. Agbim, S. Karri, S. D. Khan, D. Maluf, J. D. Eason, S. K. Satapathy, +1 Additional Author
Longitudinal Renal Function In Liver Transplant Recipients With Acute-On-Chronic Liver Failure, M. Yazawa, B. Maliakkal, S. Nair, P. S. Podila, U. A. Agbim, S. Karri, S. D. Khan, D. Maluf, J. D. Eason, S. K. Satapathy, +1 Additional Author
Journal Articles
No abstract provided.
Liver Injury In Covid-19: The Hepatic Aspect Of The Respiratory Syndrome — What We Know So Far, P. Anirvan, P. Bharali, M. Gogoi, P. J. Thuluvath, S. P. Singh, S. K. Satapathy
Liver Injury In Covid-19: The Hepatic Aspect Of The Respiratory Syndrome — What We Know So Far, P. Anirvan, P. Bharali, M. Gogoi, P. J. Thuluvath, S. P. Singh, S. K. Satapathy
Journal Articles
© 2020. All Rights Reserved. The 2019 novel coronavirus disease (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to global public health. Although primarily, the infection causes lung injury, liver enzyme abnormalities have also been reported to occur during the course of the disease. We conducted an extensive literature review using the PubMed database on articles covering a broad range of issues related to COVID-19 and hepatic injury. The present review summarizes available information on the spectrum of liver involvement, the possible mechanisms and risk factors of liver injury due to SARS-CoV-2 …
A Pilot Study Of Ex-Vivo Mri-Pdff Of Donor Livers For Assessment Of Steatosis And Predicting Early Graft Dysfunction, S. K. Satapathy, H. C. Gonzalez, J. Vanatta, A. Dyer, W. Angel, S. S. Nouer, M. Kocak, S. K. Kedia, Y. Jiang, J. D. Eason, +11 Additional Authors
A Pilot Study Of Ex-Vivo Mri-Pdff Of Donor Livers For Assessment Of Steatosis And Predicting Early Graft Dysfunction, S. K. Satapathy, H. C. Gonzalez, J. Vanatta, A. Dyer, W. Angel, S. S. Nouer, M. Kocak, S. K. Kedia, Y. Jiang, J. D. Eason, +11 Additional Authors
Journal Articles
No abstract provided.
Pro: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes, U. Agbim, S. K. Satapathy
Pro: Portal Vein Thrombosis Impacts Liver Transplantation Outcomes, U. Agbim, S. K. Satapathy
Journal Articles
No abstract provided.
Glecaprevir/Pibrentasvir In Patients With Hepatitis C Virus Genotype 1 Or 4 And Past Direct-Acting Antiviral Treatment Failure, F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hezode, F. Felizarta, R. W. Reindollar, D. E. Bernstein, F. J. Mensa, +10 Additional Authors
Glecaprevir/Pibrentasvir In Patients With Hepatitis C Virus Genotype 1 Or 4 And Past Direct-Acting Antiviral Treatment Failure, F. Poordad, S. Pol, A. Asatryan, M. Buti, D. Shaw, C. Hezode, F. Felizarta, R. W. Reindollar, D. E. Bernstein, F. J. Mensa, +10 Additional Authors
Journal Articles
No abstract provided.
Ribavirin Dose Management In Hcv Patients Receiving Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With Ribavirin, J. J. Feld, D. E. Bernstein, Z. Younes, H. Van Vlierberghe, L. Larsen, F. Tatsch, P. Ferenci
Ribavirin Dose Management In Hcv Patients Receiving Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With Ribavirin, J. J. Feld, D. E. Bernstein, Z. Younes, H. Van Vlierberghe, L. Larsen, F. Tatsch, P. Ferenci
Journal Articles
No abstract provided.
Extracorporeal Cellular Therapy (Elad) In Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial, J. Thompson, N. Jones, A. Al-Khafaji, S. Malik, D. Reich, S. Munoz, R. Macnicholas, T. Hassanein, A. Duddempudi, R. Subramanian, +33 Additional Authors
Extracorporeal Cellular Therapy (Elad) In Severe Alcoholic Hepatitis: A Multinational, Prospective, Controlled, Randomized Trial, J. Thompson, N. Jones, A. Al-Khafaji, S. Malik, D. Reich, S. Munoz, R. Macnicholas, T. Hassanein, A. Duddempudi, R. Subramanian, +33 Additional Authors
Journal Articles
No abstract provided.
Glecaprevir And Pibrentasvir For 12 Weeks For Hepatitis C Virus Genotype 1 Infection And Prior Direct-Acting Antiviral Treatment, F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, D. E. Bernstein, F. J. Mensa, +6 Additional Authors
Glecaprevir And Pibrentasvir For 12 Weeks For Hepatitis C Virus Genotype 1 Infection And Prior Direct-Acting Antiviral Treatment, F. Poordad, F. Felizarta, A. Asatryan, M. S. Sulkowski, R. W. Reindollar, C. S. Landis, S. C. Gordon, S. L. Flamm, D. E. Bernstein, F. J. Mensa, +6 Additional Authors
Journal Articles
No abstract provided.
Simeprevir Plus Sofosbuvir (12 And 8 Weeks) In Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: Optimist-1, A Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, +8 Additional Authors
Simeprevir Plus Sofosbuvir (12 And 8 Weeks) In Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: Optimist-1, A Phase 3, Randomized Study, P. Kwo, N. Gitlin, R. Nahass, D. Bernstein, K. Etzkorn, S. Rojter, E. Schiff, M. Davis, P. Ruane, J. Witek, +8 Additional Authors
Journal Articles
No abstract provided.
Efficacy Of Sofosbuvir, Velpatasvir, And Gs-9857 In Patients With Hepatitis C Virus Genotype 2, 3, 4, Or 6 Infections In An Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, +14 Additional Authors
Efficacy Of Sofosbuvir, Velpatasvir, And Gs-9857 In Patients With Hepatitis C Virus Genotype 2, 3, 4, Or 6 Infections In An Open-Label, Phase 2 Trial, E. J. Gane, K. V. Kowdley, D. Pound, C. A.M. Stedman, M. Davis, K. Etzkorn, S. C. Gordon, D. Bernstein, P. Y. Kwo, M. H. Nguyen, +14 Additional Authors
Journal Articles
© 2016 AGA Institute Background & Aims Studies are needed to determine the optimal regimen for patients with chronic hepatitis C virus (HCV) genotype 2, 3, 4, or 6 infections whose prior course of antiviral therapy has failed, and the feasibility of shortening treatment duration. We performed a phase 2 study to determine the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in these patients. Methods We performed a multicenter, open-label trial at 32 sites in the United States and 2 sites in New Zealand from …
Efficacy Of Direct-Acting Antiviral Combination For Patients With Hepatitis C Virus Genotype 1 Infection And Severe Renal Impairment Or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, +4 Additional Authors
Efficacy Of Direct-Acting Antiviral Combination For Patients With Hepatitis C Virus Genotype 1 Infection And Severe Renal Impairment Or End-Stage Renal Disease, P. J. Pockros, K. R. Reddy, P. S. Mantry, E. Cohen, M. Bennett, M. S. Sulkowski, D. E. Bernstein, D. E. Cohen, N. S. Shulman, E. Lawitz, +4 Additional Authors
Journal Articles
© 2016 AGA Institute. Background & Aims Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD). Methods We performed a single-arm, multicenter study of treatment-naïve adults with HCV genotype 1 infection, without cirrhosis and with CKD stage 4 (estimated glomerular filtration rate, 15-30 mL/min/1.73 m2) or …
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir In Patients With Hepatitis C Virus Genotype 3 Infection: Ally-3 Phase Iii Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, +15 Additional Authors
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir In Patients With Hepatitis C Virus Genotype 3 Infection: Ally-3 Phase Iii Study, D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros, N. Gitlin, B. F. Freilich, Z. H. Younes, D. Berastein, E. A. Hughes, +15 Additional Authors
Journal Articles
Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all-oral regimens requiring 24-week treatment and the addition of ribavirin (RBV). This phase III study (ALLY-3; : NCT02032901) evaluated the 12-week regimen of daclatasvir (DCV; pangenotypic nonstructural protein [NS]5A inhibitor) plus sofosbuvir (SOF; pangenotypic NS5B inhibitor) in patients infected with genotype 3. Patients were either treatment naive (n=101) or treatment experienced (n=51) and received DCV 60 mg plus SOF 400 mg once-daily for 12 weeks. Coprimary endpoints were the proportions of treatment-naive and treatment-experienced patients achieving a sustained virological response (SVR) at …